Quintrio
Home

Stock overview

Phoenix Asia Holdings Limited Ordinary Shares

PHOE

Phoenix Asia Holdings Ltd operates its business through its indirectly wholly-owned Operating Subsidiary. It is engaged in substructure works, such as site formation, ground investigation, and foundation works, in Hong Kong. To a lesser extent, the company also provides other construction services such as structural steelworks.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $15.30 – $17.93
Volume 2,214
Market cap $352M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for PHOE.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for PHOE.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Phoenix Asia Holdings (PHOE) Stock Surges Over 47% After Hours: Here's Why

Phoenix Asia Holdings announced a $1 billion stock acquisition agreement to acquire clinical-stage pharmaceutical firm ACEA Pharma Inc., marking a strategic pivot from construction into oncology and autoimmune drug development. The stock surged 47.43% in after-hours trading to $28.10, though it closed the regular session down 33.36% at $19.06. The deal requires Hart-Scott-Rodino antitrust clearance and Nasdaq review, with closing expected in Q2 2026.

Benzinga

Why Is Phoenix Asia Stock Gaining Today?

Phoenix Asia Holdings (NASDAQ: PHOE) stock gained 0.19% on Thursday following the announcement of a $1 billion acquisition agreement to purchase 100% of ACEA Pharma, Inc. through the issuance of 100 million shares at $10 each. The deal is expected to close by end of Q2 2026 and marks the company's expansion into the pharmaceutical sector while maintaining its core construction operations in Hong Kong.

GlobeNewswire Inc.

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

Scilex Holding Company announced that its subsidiaries ACEA Therapeutics and ACEA Pharma entered into a definitive agreement to sell 100% of ACEA Pharma's equity to Phoenix Asia Holdings Limited for $1 billion in newly-issued shares. Upon closing, Phoenix will be renamed ACEA Pharma and listed on Nasdaq, with ACEA Thera retaining approximately 82% ownership. The transaction is expected to close by end of Q2 2026, subject to regulatory and stock exchange approvals.

Benzinga

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

Scilex Holding Company's subsidiaries ACEA Therapeutics and ACEA Pharma have entered into a definitive stock acquisition agreement with Phoenix Asia Holdings Limited. Under the deal, ACEA will transfer 100% of ACEA Pharma's equity to Phoenix in exchange for 100 million newly-issued ordinary shares at $10 per share, valuing the transaction at $1 billion. Upon closing, Phoenix will be renamed ACEA Pharma, Inc. and its stock is expected to list on Nasdaq. The transaction is expected to close by end of Q2 2026, subject to regulatory approvals.

GlobeNewswire Inc.

The 33rd China Cycle 2025 Grandly Commence

The 33rd China Cycle Expo 2025 opened in Shanghai, showcasing the latest innovations and trends in the global cycling industry. The event featured leading brands, new technologies, and a focus on industry transformation and upgrading.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.